Extracellular DNA-associated inflammation in colorectal cancer metastasis: A testable TLR9-NF-κB-SPHK1/S1P framework and translational research agenda
Colorectal cancer (CRC) metastasis, particularly liver metastasis, remains a major cause of treatment failure.Extracellular DNA (eDNA) released from neutrophil extracellular traps, damaged mitochondria, dying tumor cells, and microorganisms can accumulate in the tumor microenvironment, circulation, and liver pre-metastatic niche.This review evaluates whether eDNA sensing may connect chronic inflammation to metastatic progression through a proposed Toll-like receptor 9 (TLR9)-nuclear factor-κBsphingosine kinase 1/sphingosine-1-phosphate framework.TLR9 is considered a candidate endosomal sensor rather than an established initiating node; cyclic GMP-AMP synthase-stimulator of interferon genes and coiled-coil domain-containing protein 25 may cooperate with or substitute for TLR9 according to ligand localization, cellular compartment, and exposure context.Nuclear factor-κB and sphingosine kinase 1/sphingosine-1-phosphate could provide transcriptional and lipid-metabolic links to invasive plasticity, myeloid immunosuppression, vascular remodeling, and therapy resistance.However, no single CRC study has demonstrated the complete cascade from a defined eDNA ligand to metastatic outgrowth using cell-specific perturbation and rescue.The current evidence is further limited by heterogeneous ligand preparation, substantial extrapolation from non-CRC models, and a lack of prospective clinical validation.We therefore present this pathway as a falsifiable research framework and outline priorities for CRC-specific organoid, orthotopic, conditional-knockout, spatial multi-omic, and longitudinal clinical studies.A multidimensional eDNA-axis signature is discussed only as an illustrative future biomarker-development framework, not as a validated score for patient management.This synthesis may help define experiments and biomarker studies needed to determine when eDNA sensing is pro-metastatic, immunostimulatory, or therapeutically actionable in CRC.
Authors
- Yu-hui Shang
- Yandong Miao (ORCID: https://orcid.org/0000-0002-1429-8915)
- Kai-Zhen Xu
- Wen-Jian Hu
- Jiu-Ning Huang
- Shuang Han
Institutions
- Shandong University of Aeronautics (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- World Journal of Translational Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.5528/wjtm.124499
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Binzhou Medical University
- FP7 Coordination of Research Activities